Overview

• Merck finalized the €3 billion purchase of US-based Springworks Therapeutics on July 1.
• The deal marks the largest pharma acquisition for Merck in nearly two decades, overtaking its 2007 Serono takeover.
• Springworks’ portfolio includes US-approved drugs for advanced soft tissue tumors and benign skin or nerve tumors that could soon enter the EU market.
• Merck expects the acquisition to deliver an immediate revenue boost in response to pressure from recent late-stage clinical trial failures.
• CEO Belén Garijo described the transaction as groundbreaking and indicated plans for further bolt-on purchases, particularly in lab equipment.